Trial Profile
A Randomized, Double-blind, Multicenter Study to Explore the Effect of GED-0301 on Endoscopic and Clinical Outcomes in Subjects With Active Crohn's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Mongersen (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 09 Jan 2019 Status changed from discontinued to completed.
- 15 Mar 2018 Status changed from active, no longer recruiting to discontinued by Sponsor following a recommendation from external DMC to terminate the ongoing Phase 3 CD studies; there were no new emergent safety findings
- 25 Aug 2017 Results published in the Gastroenterology